RABNIL-DSR
Description
- Combines acid suppression and prokinetic therapy
- Rabeprazole 20 mg (EC): Potent and fast-acting proton pump inhibitor
- Domperidone (SR): Improves gastric motility and relieves nausea
- Ideal for GERD, functional dyspepsia, gastritis, and reflux esophagitis
- Enteric-coated and sustained-release pellets for extended action
- Promotes healing of acid-induced mucosal damage
- Convenient once-daily dosing improves compliance
Composition
RABEPRAZOLE-20 MG (PEIIETS), DOMPERIDONE (PEIIETS), SR
Benefits
RABNIL-DSR offers comprehensive symptom control in upper gastrointestinal conditions by targeting both acid production and delayed gastric emptying. Rabeprazole ensures fast and effective suppression of gastric acid, promoting healing of ulcers and preventing acid reflux, while Domperidone provides sustained relief from nausea, bloating, and abdominal discomfort. The unique pellet formulation ensures controlled release and longer duration of action, making it ideal for patients requiring consistent symptom control throughout the day. RABNIL-DSR improves digestive comfort and enhances patient quality of life with convenient once-daily dosing.
Introduction
RABNIL-DSR is a dual-action gastrointestinal formulation combining Rabeprazole 20 mg (EC pellets) and Domperidone (SR pellets). Rabeprazole, a proton pump inhibitor, effectively suppresses gastric acid secretion, offering relief from acid reflux and peptic ulcers. Domperidone, a prokinetic agent, enhances gastric motility and helps relieve symptoms such as bloating, nausea, and fullness by promoting faster gastric emptying. The enteric-coated and sustained-release pellet technology ensures optimal absorption and prolonged action, making RABNIL-DSR a reliable solution for managing GERD, dyspepsia, and other acid-related disorders.
